The tumor stromal environment can dictate many aspects of tumor progression. A complete understanding of factors driving stromal activation and their role in tumor metastasis is critical to furthering research with the goal of therapeutic intervention. Polyoma middle T-induced mammary carcinomas lacking the type II TGF-β receptor (PyMTmgko) are highly metastatic compared with control PyMT-induced carcinomas (PyMTfl/fl). We hypothesized that the PyMTmgko-activated stroma interacts with carcinoma cells to promote invasion and metastasis. We show that the extracellular matrix associated with PyMTmgko tumors is stiffer and has more fibrillar collagen and increased expression of the collagen crosslinking enzyme lysyl oxidase (LOX) compared with PyMTfl/fl mammary carcinomas. Inhibition of LOX activity in PyMTmgko mice had no effect on tumor latency and size, but significantly decreased tumor metastasis through inhibition of tumor cell intravasation. This phenotype was associated with a decrease in keratin 14–positive myoepithelial cells in PyMTmgko tumors following LOX inhibition as well as a decrease in focal adhesion formation. Interestingly, the primary source of LOX was found to be activated fibroblasts. LOX expression in these fibroblasts can be driven by myeloid cell-derived TGF-β, which is significantly linked to human breast cancer. Overall, stromal expansion in PyMTmgko tumors is likely caused through the modulation of immune cell infiltrates to promote fibroblast activation. This feeds back to the epithelium to promote metastasis by modulating phenotypic characteristics of basal cells. Our data indicate that epithelial induction of microenvironmental changes can play a significant role in tumorigenesis and attenuating these changes can inhibit metastasis. Cancer Res; 73(17); 5336–46. ©2013 AACR.
The stromal microenvironment of a tumor is an essential component of tumor progression (1). Composed of various resident and recruited cell types as well as extracellular proteins, the stromal components can determine phenotypic characteristics and ultimately patient outcome. By providing growth factors and other migratory signals as well as depositing scaffolding proteins, the tumor stroma can effectively drive or impede a tumor cell toward intravasation and metastatic colonization (2). Specifically, matrix deposition and remodeling, largely facilitated through fibroblast mediators, promotes tumor growth and migration (3). While stromal influence is acknowledged, a full understanding of the signals driving the formation of a tumor promoting stroma as well as the reciprocal response of the epithelium to these changes has yet to be obtained. Insights into these interactions will provide the backbone for future therapeutic interventions specifically targeting tumor–stromal crosstalk.
Extracellular matrix (ECM) proteins, and in particular collagen, are a major component of the tumor microenvironment and exert significant effects on the tumor epithelium (4). Through its integrin mediators, ECM proteins encourage tumor growth and invasiveness. Increased mammographic density, which is significantly associated with collagen levels, independently predicts increased probability of occurrence of breast cancer in patients (5). These results are mimicked in murine models of breast cancer progression in which deposition of collagen that is unable to be proteolytically cleaved results in increased tumor formation as well as increased lung metastasis (6). Recently, it has been appreciated that ECM-epithelial crosstalk is not only mediated by the ECM proteins themselves, but by the orientation and crosslinking status of the collagen fibers. Lysyl oxidase (LOX) is a matrix-modifying enzyme that cross-links and stiffens collagen fibers to promote their stability (3). LOX has garnered interest in breast cancer as an important enzyme regulating stromal modification to drive malignant progression (3). Although epithelial LOX has been implicated in tumor metastasis through the promotion of a TGF-β–driven epithelial to mesenchymal transition (EMT) and integrin-mediated epithelial invasion (7), the role of stromal LOX in tumor metastasis has yet to be examined.
Previous work from our laboratory showed that abrogation of TGF-β signaling in epithelia results in a significant increase in PyMT-driven mammary carcinoma metastasis (8). Looking at the primary tumor for a potential cause of this phenotype, one of the most striking observations was an expansion of the stromal microenvironment (9). As these tumors presented with increased levels of TGF-β derived from infiltrated myeloid-derived suppressor cells and an increase in α-SMA–positive fibroblasts, we hypothesize that these activated fibroblasts are driving stromal expansion through the increased expression of LOX. The current study aimed to identify differentially regulated matrix-associated genes resulting in increased stromal expansion in the PyMTmgko model of breast cancer and to examine their role in driving epithelial cell phenotypes, which ultimately results in metastasis. To address this question, we used our established PyMTmgko model of mammary tumor progression. The findings show that TGF-β secreted by myeloid cells induces expression of LOX by carcinoma-associated fibroblasts, which in turn increases matrix crosslinking and stiffness to drive keratin 14 cell FAK signaling, carcinoma cell intravasation, and metastasis.
Materials and Methods
TβRII(fl/fl) mice were crossed with MMTV-PyVmT/MMTV-Cre/TβRII(fl/fl) transgenic mice to produce the TβRII(fl/fl)/PyMT (PyMTfl/fl) and TβRII(fl/fl)/PyMT/MMTV-Cre (PyMTmgko)mice. Cell lines were isolated from these spontaneous tumors and used in further in vitro experimentation. LOX inhibition studies used beta-aminopropionitrile (BAPN; 3 mg/mL, Sigma) dissolved in the drinking water. Mice were housed and handled according to approved Institutional Animal Care and Use Committee protocols.
Lung whole mount and circulating tumor cell analysis
Lungs were fixed in 10% neutral-buffered formalin overnight at 4°C. The next day, lungs were dehydrated, placed in xylene for 1 hour, and then changed to fresh xylene overnight. Lungs were rehydrated before dipping in Mayer hematoxylin for 2 minutes and then washed in running tap water for 5 minutes. Tissues were destained in HCl (fresh 1% v/v from a 12 N solution) for 20 minutes, rinsed in running tap water overnight, dehydrated, and placed in xylene overnight before counting stained metastatic tumor foci under a dissecting light microscope.
Circulating blood was isolated from the left ventricle of tumor-bearing mice upon sacrifice. Two hundred microliters of the blood was plated into a well of a gelatin-coated 6-well dish and allowed to grow for 3 to 4 weeks. After the growth phase, colonies larger than 150 μm were counted and quantified.
Picrosirius Red staining and quantification
Five-micron sections of paraffin-embedded mammary tumors were stained with 0.1% Picrosirius Red (Direct Red 80; Sigma Aldrich). Stained sections were imaged on a Zeiss Axiophot equipped with a cross-polarizer. Images were quantified for pixel density of thresholded light intensity (3).
In situ hybridization
The following protocol was carried out on sections of fresh frozen tumor tissue. In brief, sections were digested with 0.125 mg/mL of pronase, fixed in 10% formalin, and blocked with 0.2% glycine. Sections were probed with digoxigenin-labeled sense and antisense probes, each approximately 300 bp in length. Probes were obtained from digestion of full-length mouse LOX cDNA with HindIII and XbaI (New England Biolabs). Following overnight probe incubation, staining was visualized through staining sections with 1:500 AP-labeled anti-DIG (Roche). Sections were counterstained with 4′,6-diamidino-2-phenylindole (DAPI; Invitrogen) for nuclei visualization (10).
Tissue preparation for AFM measurements of ECM stiffness
Mammary glands were analyzed following cryopreservation. Fresh glands were embedded in OCT (Tissue-Tek) aqueous embedding compound within a disposable plastic base mold (Fisher) and were snap frozen by direct immersion into liquid nitrogen. Frozen tissue blocks were then cut into 20 μm sections using disposable low profile microtome blades (Leica, 819) on a cryostat (Leica, CM1900-3-1). Before the AFM measurement, each section was thawed by immersion in PBS at room temperature. The samples were maintained in proteinase inhibitor in PBS (protease inhibitor cocktail; Roche Diagnostics, 11836170001), with propidium iodide (SIGMA P4170, 20 μg/mL) during the AFM session.
Two-photon microscopy image acquisition and analysis
For two-photon imaging, we used custom resonant-scanning instruments based on published designs containing a 5-PMT array (Hamamatsu, C7950) operating at video rate (11). The setup was used with 2 channel simultaneous video rate acquisition via 2 PMT detectors and an excitation laser (2W MaiTai Ti-Sapphire laser, 710–920 nm excitation range). Second harmonics imaging was carried out on a Prairie Technology Ultima System attached to an Olympus BX-51 fixed stage microscope equipped with a ×25 (NA 1.05) water immersion objective. Unfixed, hydrated samples were exposed to polarized laser light at a wavelength of 830 nm and emitted light was separated with a filter set (short pass filter, 720 nm; dichroic mirror, 495 nm; band pass filter, 475/40 nm). Images of x and y planes of 284 by 284 μm at a resolution of 0.656 μm/pixel were captured using Micro-Manager Open Source Microscopy Software (Micro-Manager) in at least 3 locations on each mammary gland. Quantification of collagen fibers was achieved by setting a minimal threshold in the second harmonic signal. The threshold was maintained for all images across all conditions. The area of regions that was covered by the minimal threshold was calculated and 3 images per sample were averaged together (Image J, Image Processing and Analysis in Java). Collagen fiber diameters data were visualized and analyzed using Imaris (Bitplane AG) and MATLAB (MathWorks).
Statistical analysis was conducted using GraphPad Prism after consultation with the Vanderbilt Biostatistics Department (Nashville, TN).
Increased collagen deposition and LOX expression in PyMTmgko tumors
The generation of mammary tumors with and without TGF-β Type II receptor has been previously described (8, 9). Prior work showed this mouse model presents with an enhanced reactive stroma and increased myofibroblast presence compared with tumors with TGF-β signaling (9). Expanding on these studies, characterization of the collagen ECM was carried out. Elevated Trichrome Blue staining and increased polarized intensity of Picrosirius Red-stained tissue suggested higher content of total and fibrillar collagen in the stroma of PyMTmgko tumors (Fig. 1A and B). qPCR analysis indicated no increased expression of collagen type I or type IV implicating collagen stablization (Supplementary Fig. S1). Second harmonics generation revealed a trend of more abundant linearized, thick collagen fibers dispersed throughout the stroma, consistent with a greater amount of cross-linked collagen present in the PyMTmgko tumors, presented and quantified in Fig. 1C. Consistently, tumor gene expression and protein levels showed that expression of the collagen crosslinking enzyme LOX was increased in the PyMTmgko tumors compared with PyMTfl/fl tumors (Fig. 1D). This protein specifically cross-links collagen fibers to regulate their stability (12). LOX was of particular interest due to its significant role in tumor progression (13). Analysis of other members of the LOX family showed no significant difference between PyMTfl/fl and PyMTmgko tumors (Supplementary Fig. S2). Concordant with increased expression of LOX, atomic force microscopy indentation quantified a significant increase in the stiffness of the ECM associated with the PyMTmgko tumors (Fig. 1E). These results indicate that rather than enhanced collagen synthesis, PyMTmgko tumors promote increased collagen stability culminating in an overall increase in collagen deposition and stiffness in the stroma associated with PyMTmgko tumors.
LOX inhibition prevents tumor cell metastasis through decreased tumor cell extravasation
TGF-β has long been known to promote metastasis in late-stage tumors through the induction of an EMT; however, epithelial loss of TGF-β signaling in our mammary tumors presents with increased metastatic burden (8). As LOX expression was significantly increased in PyMTmgko tumors, the effect of this increased expression on the enhanced lung metastasis of the PyMTmgko tumors was examined. BAPN, a synthetic chemical inhibitor of LOX activity that mimics the efficacy of LOX inhibitory antibodies and was used in our mouse model (13–15). Treatment of PyMTmgko mice with BAPN resulted in no significant change in time to tumor palpation (Fig. 2A). Atomic force microscopy indentation mapping carried out on those tumors treated with and without BAPN showed a significant reduction in the tensile strength of the stromal regions of these tissues (Fig. 2B). Histologic analysis of the primary tumor showed no changes to the composition or characteristics of the tumor epithelium or stromal infiltrates (Fig. 2C). BAPN treatment also did not cause any significant changes in tumor volume in PyMTmgko mice (Fig. 2D). However, upon examination of lung whole mounts from PyMTmgko mice with and without BAPN treatment, there was a significant decrease in the incidence of lung metastasis following BAPN treatment (Fig. 2E). In addition, in those PyMTmgko mice that did harbor lung metastasis upon BAPN treatment, the number of lung metastasis was significantly lower than in the untreated PyMTmgko mice (Fig. 2F). In the cascade of metastatic progression, intravasation from the primary tumor into the vasculature is one of the first steps (16). Upon examination, we noted a reduced numbers of viable tumor cells in the circulation, suggesting that LOX inhibition significantly reduced metastasis by inhibiting tumor cell intravasation (Fig. 2G). As premetastatic niche effects of LOX have been established (17), tail vein injection experiments into mice with and without BAPN treatment were conducted and showed no differences in metastatic colonization potential (Supplementary Fig. S3). Thus, these data suggest that LOX promotes tumor cell metastasis in PyMTmgko tumors by enhancing intravasatation into the vasculature.
LOX promotes keratin 14 myoepithelial cells
As we showed that LOX promoted tumor cell escape from the primary tumor into the vasculature, we next looked for correlations between LOX and phenotypic molecular changes associated with highly aggressive, metastatic tumors. Gene expression analysis revealed that LOX inhibition in PyMTmgko tumors decreased the expression of keratin 14 (Fig. 3A). These findings were supported by immunofluorescence that showed that PyMTmgko tumors were highly enriched for K14 cells, particularly at the epithelial stromal interface, implicating a role for collagen interaction in this phenotype. Indeed, BAPN-treated tumors showed a significant reduction in K14+ epithelial cells (Fig. 3B and Supplementary Fig. S4). These findings are consistent with the basal subtype of breast cancer, which presents with increased metastasis and poor patient survival (18). As myoepithelial cells represent a highly contractile, matrix-responsive cell population and previous studies indicated that LOX-mediated collagen cross-linking and stiffening promote the formation of focal adhesions (3, 19, 20), we addressed the relationship between these 2 phenotypes. Upon treatment with BAPN, levels of pFAK-397 relative to total FAK were decreased in total tumor lysates (Fig. 3C). Immunofluorescence of PyMTmgko tumors either untreated or treated with BAPN stained for keratin 14 and pFAK showed that decreased pFAK-397 staining in BAPN-treated tumors (Fig. 3D and Supplementary Fig. S5). In PyMTmgko tumors, the K14 cell population was highly enriched for pFAK staining, with both being localized at the tumor–stromal interface. Upon BAPN treatment, this enrichment of pFAK staining in these cells was diminished. These data revealed that LOX inhibition results in a loss of the keratin 14-positive myoepithelial cell phenotype in PyMTmgko tumor cells and that this loss is linked with a corresponding loss of focal adhesion formation.
Stromal cells represent the primary source of LOX in PyMT tumors
Tumor cells cultured under hypoxic conditioned or expressing high levels of HIF1α express higher levels of LOX than their nonhypoxic counterparts (13). Thus, the increased expression of LOX could be attributed to elevated tissue hypoxia (13, 19). However, we could not establish any consistent relationship between level or distribution of tumor hypoxia when comparing the PyMTfl/fl and PyMTmgko tumors (Supplementary Fig. S6). Alternately, in human breast carcinoma, LOX expression is also a stromally produced gene that is coexpressed along with collagen type I (3, 21). Gene expression analysis on cell lines indicates that fibroblasts consistently expressed significantly more LOX when compared with epithelial tumor cells (Fig. 4A). To validate these in vitro findings in vivo, laser capture microdissection (LCM) was carried out on tumor sections to isolate RNA from either epithelial or stromal regions of the tumor. Upon qPCR analysis, the stroma of PyMTmgko tumors expressed approximately 10-fold more LOX than the neighboring epithelium (Fig. 4B). In situ hybridization for LOX mRNA again showed that the stromal regions of PyMTmgko tumors were highly enriched for LOX mRNA compared with the epithelium (Fig. 4C and Supplementary Fig. S7). To verify the validity and relevance of such findings to human disease, publicly available datasets of LCM epithelium and stroma from invasive ductal carcinoma (IDC) were analyzed to localize LOX expression. Indeed, matching the finding in the PyMTmgko tumors, IDC tumors quantitatively showed a marked increase in LOX expression in the stroma compared with the epithelium. LOX expression also aligned with genes known to be expressed in activated myofibroblasts, connective tissue growth factor (CTGF), and α-smooth muscle actin (ACTA2) all of whose expression was increased in the stroma (Fig. 4D and E; ref. 22). These results indicated that in both murine PyMT tumors as well as human IDC, the stroma is an abundant source of LOX.
TGF-β from infiltrating myeloid cells can drive fibroblast LOX expression
We previously reported that PyMTmgko tumors are characterized by increased myeloid-derived suppressor cell infiltration (MDSC; refs. 23). MDSCs secrete abundant quantities of TGF-β into the tumor microenvironment (23). TGF-β is a classically defined cytokine responsible for the activation of fibroblasts to α-SMA–expressing myofibroblasts. Corresponding with this fibroblast activation, in other mesenchymal cell types, such as lung fibroblasts and cardio myofibroblasts, TGF-β induces LOX expression in a Smad-AP1–dependent manner (24–26). When examining in vivo tumor progression, we observed a regional colocalization of Gr1+ myeloid cells and α-SMA–expressing fibroblasts (Fig. 5A). This regional distribution and colocalization of Gr1+ cells and α-SMA fibroblasts was consistent with the nonuniform, linearized collagen fibers we observed at the tumor periphery by second harmonic generation imaging (Fig. 5B). Consistent with regional infiltration of MDSCs inducing local collagen remodeling, we quantified a spectrum of focally stiffened ECM by atomic force microscopy indentation (Fig. 5C). Supporting the role of LOX in this phenotype, we observed that BAPN treatment significantly reduced this variability, normalizing collagen fiber thickness and reducing stromal stiffness. To investigate the potential role of Gr1+ MDSC-derived TGF-β in driving stromal LOX expression in PyMTmgko tumors, a mouse mammary fibroblast cell line was treated with conditioned media from Gr1+ cells and Gr1− cells isolated from the spleens of PyMTmgko tumor-bearing mice. These experiments were conducted with the use of the ALK 4, ALK5, and ALK7 inhibitor SB431542 to examine the necessity for TGF-β in any observed gene expression changes (27). Upon treatment, both Gr1+- and Gr1−-conditioned media were able to induce expression of α-SMA, a marker of fibroblast transition to an activated state in a TGF-β–dependent manner. However, only TGF-β from Gr1+ cell-conditioned media was able to induce the expression of LOX (Fig. 5D). Interestingly, TGF-B had no such induction of LOX expression from epithelial tumor cells (Supplementary Fig. S8). These data were verified by examining LOX protein levels as well as activity in the conditioned media of mouse mammary fibroblasts treated with Gr1+ and Gr1−-conditioned media (Supplementary Fig. S9) implicating Gr1+-derived TGF-β as a driver of stromal LOX expression in PyMTmgko tumors. Additional support for this idea comes from analysis of publically available human stromal microarray datasets, which showed that stromal expression of TGF-β1 is significantly correlated with stromal LOX expression (Fig. 5E). Together, these data strongly suggest that stromally expressed TGF-β acts on fibroblasts to promote the expression and activity of LOX.
The microenvironment is an essential component in promoting tumors toward metastasis (28). While significant effort has been placed on the cellular components of the microenvironment, such as immune cells, fibroblasts, and endothelial cells, one of the most interesting components is the ECM. The ECM acts as a foundation upon which tumors build themselves, a scaffold for blood and lymphatic vessels, and a trigger for integrin to mediate cellular changes to promote growth and migration (29). As breast cancer with abrogated TGF-β signaling have substantially worse disease-free survival, we sought to address the role an altered collagen matrix played in the aggressiveness of tumors (30, 31). In PyMTmgko tumors, a significant increase in collagen remodeling and LOX expression was observed. LOX is increased in breast cancer and associated with poor patient prognosis/metastasis (NextBio). We observed that inhibition of LOX significantly reduced tumor metastasis through decreased tumor cell intravasation. Our data indicate that LOX is stromally derived in PyMTmgko tumors, thus LOX acts as a promoter of tumor metastasis independent of the cellular source and potentially through similar mechanisms. Interestingly, it seems that stromal TGF-β signaling drives this increase in LOX expression. The evidence for TGF-β promoting LOX expression and matrix remodeling thus adds another layer of complexity to the premise of therapeutically targeting TGF-β in the context of cancer.
Various tumor characteristics have been attributed to alterations of the collagenous microenvironment in tumors. Notably, hypoxic conditions drive the expression of LOX from tumor epithelium (13). As a driver for many of the phenotypes observed in our PyMTmgko tumors, hypoxia was a prospective candidate for our enhanced tumorigenesis. However, no difference in hypoxia was seen leading us to look elsewhere. Previous work from our laboratory has shown that epithelial loss of functional TGFβR2 expression results in an increased recruitment of MDSCs and that this promotes tumor progression to metastasis (23). These cells are a major source of TGF-β in tumors. We show that these immature myeloid cells localize to areas of α-SMA expression in PyMTmgko tumors and can promote tumor matrix remodeling through TGF-β–mediated stimulation of stromal fibroblasts, specifically via induced expression of LOX. It has been previously established that lung fibroblasts, as well as cardiac myofibroblasts, can express LOX upon TGF-β stimulation (24, 25). We show that this LOX-promoting source of TGF-β from fibroblasts can be tumor-infiltrating immune cells. Our study suggests that the tumor epithelium can indirectly promote an aggressive microenvironment through the facilitation of interactions of various components of the tumor microenvironment.
LOX is known to promote focal adhesion formation in mammary carcinoma cells and in vivo inhibition of LOX suppresses both hypoxic and nonhypoxic tumor metastasis (3). Using a different mouse model of breast cancer, we have recapitulated these findings of decreased focal adhesion formation and metastasis upon inhibition of LOX with BAPN. While it should be noted that BAPN has been reported to have effects on members of the LOX family, we did not see any appreciable changes in LOXL expression (Supplementary Fig. S2) and while certainly not quantitative, the relative Ct values for the LOXL qPCR were significantly lower than those for LOX, indicating lower gross expression in our tumors. As LOX acts to crosslink extracellular collagen and elastin, the induction of these phenotypes is likely due to its ability to promote stiffness in the tumor microenvironment (3, 32). Increased matrix stiffness leads to an EMT in tumor epithelium, which led us to ask whether the inhibition of LOX in our spontaneous tumors resulted in decreased circulating tumor cells and metastasis through the prevention of this transition (33). While no difference in the induction of EMT was observed, most likely due to a lack of TGF-β responsiveness in tumor cells used, we did see an increase in keratin 14 expression. While previously basal breast cancer cells have been shown to secrete LOX, this was the first instance in which we see LOX activity regulating this tumor cell phenotype (13, 34). Live cell imaging of K14+ mammary epithelium has shown these cells to be highly protrusive and migratory specifically in response to a collagen matrix (35). As collagen was shown to be the main driver of this migratory phenotype, modulation of the collagen matrix could abrogate this effect. This indeed turned out to be the case in that inhibition of LOX resulted in fewer K14+ cells. Linking this aggressive basal phenotype with previous findings regarding the effects of LOX on the tumor epithelium, we find that K14 cells are enriched for the formation of focal adhesions in our PyMTmgko tumors. The ability to adhere and respond to the ECM is an essential step in obtaining a migratory phenotype and promoting metastasis of tumor cells. As expected, inhibition of LOX activity diminished this focal adhesion enrichment. This, potentially, links not only the epithelial phenotype of these cells with their ability to respond to matrix cues, in particular matrix crosslinking and stiffness, but also to the decrease in metastasis through diminished tumor cell intravasation.
The data presented in this study show that microenvironmental changes have significant effects on tumor progression. We show that the aggressiveness of tumor epithelium is not only dictated by the genetic programming of the tumor cell but also by the state of the ECM. By showing that inhibition of LOX activity can not only inhibit tumor cell metastasis, but also modulate the phenotypic characteristics of the tumor cells, we have further refined the conceptual framework used for stromally targeted therapeutics. Showing that myeloid cell infiltrates can arouse stromal activation should widen the breadth of patients considered for immune modulating treatments and also provide new readouts for the efficacy of treatment options. However, while addressing many pressing issues in the field of cancer biology, our data also raise some interesting questions. We show that ECM modifications can drive phenotypic changes in basal cells; thus, it is now necessary to identify the molecular basis for this interaction. Both growth factor responsiveness as well as adhesion have been shown to regulate cellular phenotypes; therefore, the ability of ECM modification to promote these signaling pathways could begin to address this phenotypic switch. It is also unclear what the specific role these basal cells play in the invasive and metastatic phenotype observed. Addressing the specific migratory and invasive capacity of these different populations of cells will aid in pushing forward our knowledge of tumor metastasis. With metastasis representing the major cause of morbidity and mortality in patients with breast cancer, a thorough understanding of stromal cues present in the tumor microenvironment and reciprocal epithelial responses to these cues in the context of tumor metastasis is essential.
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.
Conception and design: M.W. Pickup, H. Laklai, V.M. Weaver, H.L. Moses
Development of methodology: M.W. Pickup, H. Laklai, V.M. Weaver
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): M.W. Pickup, H. Laklai, I. Acerbi, P. Owens, A.E. Gorska, A. Chytil, V.M. Weaver
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): M.W. Pickup, H. Laklai, I. Acerbi, P. Owens, V.M. Weaver
Writing, review, and/or revision of the manuscript: M.W. Pickup, H. Laklai, V.M. Weaver, H.L. Moses
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): M.W. Pickup, P. Owens, A.E. Gorska, A. Chytil, M. Aakre
Study supervision: V.M. Weaver
The authors thank the Biological Imaging Development Center at UCSF for the use of 2-photon microscope image acquisition and image processing facilities. The authors also thank all the members of the Moses and Weaver Labs for critical help with experimentation and general discussion.
This work is supported by NIH grants CA085492 and CA151925 (H.L. Moses and V.M. Weaver) CA102162 (H.L. Moses), CA126505 and CA138818 (V.M. Weaver), Susan G Komen award PDF12230246 (I. Acerbi), the T.J. Martell Foundation (H.L. Moses), and CA068485 for core laboratory support.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.